Key Takeaways
- • Corxel Pharmaceuticals Inc., an obesity-focused biopharmaceutical company, unveiled plans on Monday, October 26, 2026 to go public by merging with special-purpose acquisition company Amanat Acquisition Corp.
- • The transaction is expected to generate roughly $377 million in gross proceeds, according to Law360.
- • Three law firms worked on structuring the deal, per the Law360 report.
Summary
Obesity-focused biopharmaceutical company Corxel Pharmaceuticals Inc. announced on Monday, October 26, 2026, that it plans to go public through a merger with special-purpose acquisition company Amanat Acquisition Corp. According to Law360, the deal is expected to generate roughly $377 million in gross proceeds.
Law360 reported that three law firms advised on the transaction, which it described as having been built by those firms. The source article is a brief report and does not detail the specific advisers, the valuation of the combined company, the expected timing of closing, or the terms of the merger agreement. Readers seeking those details should consult the original filings or subsequent coverage.
The transaction reflects continued use of the SPAC structure by late-stage and clinical-stage life sciences companies seeking public-market access, with the obesity therapeutics sector drawing significant investor interest.
Law360 reported that three law firms advised on the transaction, which it described as having been built by those firms. The source article is a brief report and does not detail the specific advisers, the valuation of the combined company, the expected timing of closing, or the terms of the merger agreement. Readers seeking those details should consult the original filings or subsequent coverage.
The transaction reflects continued use of the SPAC structure by late-stage and clinical-stage life sciences companies seeking public-market access, with the obesity therapeutics sector drawing significant investor interest.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.